Interferon News and Research

RSS

SARS-CoV-2 delays interferon signaling in host cells

A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.

7 Feb 2021

New combination therapy proven to be highly effective in HBV infection model

Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer.

4 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

A new preprint examines Long COVID-19, aiming to identify the underlying immunologic status in such patients.

3 Feb 2021

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

2 Feb 2021

Differences in immune response to SARS-CoV-2 determine disease severity, study finds

Researchers investigate host responses to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.

2 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

Elevated ACE2 and inflammation levels increase risk for pregnant women infected with SARS-CoV-2

Among the hundred million or so cases of coronavirus disease 2019 (COVID-19) that have occurred since the pandemic began, pregnant women have been a conspicuous risk group. However, the exact nature of the risk they and their fetuses face, and the mechanism by which it operates, is far from clear.

2 Feb 2021

Early-life-trauma could affect trajectory of multiple sclerosis development and treatment

Childhood trauma could affect the trajectory of multiple sclerosis development and response to treatment in adulthood, a new study in mice found.

29 Jan 2021

What do we know about the SARS-CoV-2 vaccines so far?

A new study surveys what we know so far about SARS-CoV-2 vaccine candidates from advanced clinical trials.

27 Jan 2021

Researchers find microbiome-controlled anti-inflammatory subsets of astrocytes

Astrocytes are the most abundant type of cells within the central nervous system (CNS), but they remain poorly characterized.

26 Jan 2021

Researchers develop method for presymptomatic COVID-19 detection

An encouraging new study by researchers at University College London, UK, reports the potential of a form of COVID-19 testing which can detect presymptomatic cases.

26 Jan 2021

SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation

Researchers at the Erasmus Medical Centre in the Netherlands and the University of Illinois at Urbana-Champaign in the US found that SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation and that this can be prevented by using cell lines with an active serine protease-mediated entry pathway.

26 Jan 2021

Transcriptional regulator BRD2 as a potential therapeutic target for COVID-19

A team of international scientists has demonstrated that therapeutic inhibition of a transcriptional regulator BRD2, required for the endogenous expression of angiotensin-converting enzyme 2 (ACE2), can potentially suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv* preprint server.

24 Jan 2021

Experts advise disaggregating data on COVID-19 patients by sex

Researchers at Yale University School of Medicine have highlighted the importance of ensuring studies of patients with coronavirus disease 2019 (COVID-19) report data in a sex-disaggregated manner.

24 Jan 2021

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Researchers provide an overview of SARS-CoV-2 and its life cycle pathways, addressing the functional changes in the viral proteins, providing important strategic clues to help that may help in the ongoing development of therapies against COVID-19.

22 Jan 2021

Study reveals new insights into how UV light triggers kidney inflammation in lupus patients

A new collaborative study from researchers at the Geisel School of Medicine at Dartmouth and the University of Washington (UW) and published in the Proceedings of the National Academy of Sciences, reveals unexpected insights into how skin exposure to ultraviolet light can worsen clinical symptoms in autoimmune diseases such as lupus.

22 Jan 2021

New model shows key role of innate immunity in controlling COVID-19 viral load

Since SARS-CoV-2 was identified in December 2019, researchers have worked feverishly to study the novel coronavirus. Although much knowledge has been gained, scientists still have a lot to learn about how SARS-CoV-2 interacts with the human body, and how the immune system fights it.

21 Jan 2021

SARS-CoV-2 suppresses host innate immunity

SARS-CoV-2, the virus that causes COVID-19, blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues.

21 Jan 2021

Scientists identify a molecular mechanism that protects the fetus from maternal infection

Researchers at Duke and Mt. Sinai have identified a molecular mechanism that prevents a viral infection during a mother's pregnancy from harming her unborn baby.

21 Jan 2021

Interferon News and Research

SARS-CoV-2 delays interferon signaling in host cells

New combination therapy proven to be highly effective in HBV infection model

Insight into role of aging in response to SARS-CoV-2 infection

Long COVID-19 symptoms not associated with reduced cell-mediated immunity, finds study

Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients

Differences in immune response to SARS-CoV-2 determine disease severity, study finds

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

Elevated ACE2 and inflammation levels increase risk for pregnant women infected with SARS-CoV-2

Early-life-trauma could affect trajectory of multiple sclerosis development and treatment

What do we know about the SARS-CoV-2 vaccines so far?

Researchers find microbiome-controlled anti-inflammatory subsets of astrocytes

Researchers develop method for presymptomatic COVID-19 detection

SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation

Transcriptional regulator BRD2 as a potential therapeutic target for COVID-19

Experts advise disaggregating data on COVID-19 patients by sex

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Study reveals new insights into how UV light triggers kidney inflammation in lupus patients

New model shows key role of innate immunity in controlling COVID-19 viral load

SARS-CoV-2 suppresses host innate immunity

Scientists identify a molecular mechanism that protects the fetus from maternal infection

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News